Newly Diagnosed Glioblastoma

A  Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.

A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.

A Phase 2 randomized trial studies the use of a PET scan with 18F-fluciclovine (Fluciclovine PET) in addition to the normal radiation planning imaging procedures (MRI and CT scan) will help determine the areas where the radiation therapy is to be delivered.